|
|
News Breaks | | | | November 12, 2012 | | 08:01 EDT |  | GALT | Galectin Therapeutics presents preclinical data on GR-MD-02
Galectin Therapeutics presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease Annual Meeting in Boston, MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of non-alcoholic steatohepatitis, or fatty liver disease. These new data help to further explain the mechanism of action of GR-MD-02, showing that this galectin inhibitor affects multiple pathways involved with both the prevention and reversal of fibrosis in NASH pathology. The new data show that Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were dramatically reduced to barely detectable levels following treatment with GR-MD-02. Elevated expression of iNOS, an important inflammatory mediator, and CD36, a scavenger receptor involved in the pathogenesis of NASH, were markedly reduced following treatment with GR-MD-02. | |
|
News For GALT From The Last 14 Days Check below for free stories on GALT the last two weeks. |
|
|
| June 12, 2013 | | 08:04 EDT | | GALT | Galectin Therapeutics announces positive results from GR-MD-02 study
Galectin Therapeutics announced that preclinical studies have shown that combining the galectin inhibitor GR-MD-02 with monoclonal antibodies that function as immune checkpoint blockade inhibitors enhance shrinkage of prostate and breast cancer tumors. he addition of GR-MD-02, a drug that inhibits galectin proteins, was found to increase tumor shrinkage and enhance survival in immune competent mice with prostate and breast cancers when combined with one of the immune checkpoint blockade inhibitors, anti-CTLA-4 or anti-PD-1. | |
|
|
|
|
|
|
